Boron Neutron Capture Therapy (BNCT) Mediated by Maleimide-Functionalized
BNCT
MID:BSA
boron neutron capture therapy
hamster cheek pouch
mucositis
new boron compounds
oral cancer
Journal
Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444
Informations de publication
Date de publication:
20 Jul 2022
20 Jul 2022
Historique:
received:
24
06
2022
revised:
11
07
2022
accepted:
14
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
BNCT (Boron Neutron Capture Therapy) is a tumor-selective particle radiotherapy that combines preferential boron accumulation in tumors and neutron irradiation. Although Biodistribution studies were performed at 30 mg B/kg and 15 mg B/kg (12 h and 19 h post-administration). MID:BSA/BNCT (15 mg B/kg, 19 h) was performed at three different absorbed doses to precancerous tissue. MID:BSA 30 mg B/kg protocol induced high BSA toxicity. MID:BSA 15 mg B/kg injected at a slow rate was well-tolerated and reached therapeutically useful boron concentration values in the tumor and tumor/normal tissue ratios. The 19 h protocol exhibited significantly lower boron concentration values in blood. MID:BSA/BNCT exhibited a significant tumor response vs. the control group with no significant radiotoxicity. MID:BSA/BNCT would be therapeutically useful to treat oral cancer. BSA toxicity is a consideration when injecting a compound conjugated to BSA and depends on the animal model studied.
Sections du résumé
BACKGROUND
BACKGROUND
BNCT (Boron Neutron Capture Therapy) is a tumor-selective particle radiotherapy that combines preferential boron accumulation in tumors and neutron irradiation. Although
METHODS
METHODS
Biodistribution studies were performed at 30 mg B/kg and 15 mg B/kg (12 h and 19 h post-administration). MID:BSA/BNCT (15 mg B/kg, 19 h) was performed at three different absorbed doses to precancerous tissue.
RESULTS
RESULTS
MID:BSA 30 mg B/kg protocol induced high BSA toxicity. MID:BSA 15 mg B/kg injected at a slow rate was well-tolerated and reached therapeutically useful boron concentration values in the tumor and tumor/normal tissue ratios. The 19 h protocol exhibited significantly lower boron concentration values in blood. MID:BSA/BNCT exhibited a significant tumor response vs. the control group with no significant radiotoxicity.
CONCLUSIONS
CONCLUSIONS
MID:BSA/BNCT would be therapeutically useful to treat oral cancer. BSA toxicity is a consideration when injecting a compound conjugated to BSA and depends on the animal model studied.
Identifiants
pubmed: 35888170
pii: life12071082
doi: 10.3390/life12071082
pmc: PMC9323568
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : FONCyT, Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación
ID : PICT-2019-00523
Organisme : Comisión Nacional de Energía Atómica
Organisme : JSPS KAKENHI
ID : 21H02066
Références
Oral Oncol. 2011 Nov;47(11):1017-22
pubmed: 21840244
J Control Release. 2016 Sep 10;237:160-7
pubmed: 27422608
J Dent Res. 1954 Apr;33(2):253-62
pubmed: 13152263
Methods Mol Biol. 2016;1422:341-50
pubmed: 27246045
Radiat Oncol. 2020 Jan 6;15(1):7
pubmed: 31906998
Appl Radiat Isot. 2015 Dec;106:237-41
pubmed: 26277052
Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):16077-81
pubmed: 25349432
Clin Oncol (R Coll Radiol). 2020 May;32(5):330-341
pubmed: 31911016
Cancer Commun (Lond). 2018 Jun 19;38(1):37
pubmed: 29914577
Oral Surg Oral Med Oral Pathol Oral Radiol. 2020 Apr;129(4):347-356
pubmed: 31928903
Head Neck. 2020 Apr;42(4):794-802
pubmed: 31898358
Appl Radiat Isot. 2009 Jul;67(7-8 Suppl):S313-7
pubmed: 19376711
Oncol Lett. 2011 Jul;2(4):637-642
pubmed: 22848241
Adv Drug Deliv Rev. 2011 Mar 18;63(3):136-51
pubmed: 20441782
Radiat Res. 2011 Apr;175(4):463-72
pubmed: 21294607
Radiat Res. 1999 Aug;152(2):113-8
pubmed: 10409319
Invest New Drugs. 2022 Apr;40(2):255-264
pubmed: 34816337
J Control Release. 2012 Jan 10;157(1):4-28
pubmed: 21959118
Cancer Commun (Lond). 2018 Jun 19;38(1):38
pubmed: 29914570
Radiat Environ Biophys. 2011 Mar;50(1):199-207
pubmed: 21132507
Cancer Res. 2001 Dec 15;61(24):8638-42
pubmed: 11751376
Appl Radiat Isot. 2009 Jul;67(7-8 Suppl):S309-12
pubmed: 19380233
Biomed Res Int. 2013;2013:736438
pubmed: 24396828
Anticancer Res. 2014 Nov;34(11):6381-8
pubmed: 25368237
Front Pharmacol. 2017 Jun 08;8:354
pubmed: 28642709
IET Nanobiotechnol. 2020 Feb;14(1):105-111
pubmed: 31935686
Adv Drug Deliv Rev. 2018 May;130:17-38
pubmed: 30009886
Oral Oncol. 2020 Mar;102:104559
pubmed: 31923856
Oral Dis. 2013 Nov;19(8):789-95
pubmed: 23410091
Med Oral Patol Oral Cir Bucal. 2005 Nov-Dec;10(5):412-21
pubmed: 16264377
J Dent Res. 1961 Jan-Feb;40:3-15
pubmed: 13772812
F1000Prime Rep. 2014 Jun 02;6:44
pubmed: 24991421
Radiother Oncol. 2021 Feb;155:182-187
pubmed: 33186684
Oral Dis. 2020 Apr 16;:
pubmed: 32297432
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):e67-75
pubmed: 21300462
Ther Deliv. 2019 Jun 1;10(6):353-362
pubmed: 31184544
Am J Physiol Gastrointest Liver Physiol. 2018 Feb 1;314(2):G231-G246
pubmed: 29074485
Oral Oncol. 2000 Jul;36(4):373-81
pubmed: 10899677
Appl Radiat Isot. 2009 Jul;67(7-8 Suppl):S50-3
pubmed: 19375342
Neurol Med Chir (Tokyo). 2018 Dec 15;58(12):487-494
pubmed: 30464150
Emerg Themes Epidemiol. 2013 Dec 13;10(1):14
pubmed: 24330636
Ther Deliv. 2015 Mar;6(3):269-72
pubmed: 25853302
Rep Pract Oncol Radiother. 2018 Sep-Oct;23(5):462-473
pubmed: 30263016
Periodontol 2000. 2015 Feb;67(1):292-311
pubmed: 25494606
In Vivo. 2019 Nov-Dec;33(6):1751-1755
pubmed: 31662499
Theranostics. 2019 Oct 17;9(26):8091-8108
pubmed: 31754383
Radiat Res. 2006 Aug;166(2):387-96
pubmed: 16881740
Radiat Environ Biophys. 2019 Aug;58(3):455-467
pubmed: 31123853
Cancer Res. 2015 Feb 1;75(3):544-53
pubmed: 25644265
Theranostics. 2019 Oct 17;9(26):8073-8090
pubmed: 31754382
Arch Oral Biol. 2007 Mar;52(3):273-9
pubmed: 17137553